Drug Trial Radar · NCT00495508
Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy
Last checked: Nov 20, 2026Latest source record: Jun 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Oct 2006
Primary completion
Jun 2009
Study completion Jun 2009
Sponsor
- Lead sponsor
- EpicentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Medecins Sans Frontieres, Netherlands; University of Cape Town; Shoklo Malaria Research Unit
- First posted
- Jul 3, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A) for the treatment of uncomplicated malaria during second and third trimester pregnancy to oral Quinine hydrochloride. The PCR-corrected adequate clinical and parasitological response (ACPR) on day 42 is considered as the primary efficacy criterion. Newborns will be followed for growth and development indicators.
Conditions
- Malaria
Interventions
QuinineDrug
artemether / lumefantrineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42 or at delivery.Time frame: 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Epicentre
Mbarara, Mbarara District, Uganda
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.